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The incidence and mortality rates for cervical cancer in Latin
America are among the highest in the world. In Peru, the age-
standardized incidence rate in 1998 was 40 per 100 000 (IARC,
1998). Cervical cancer is the leading cause of death among
Peruvian women, with a mortality rate of 22 per 100 000 (IARC,
1998). It often strikes women during the peak of their economic
activity leaving behind young children without mothers. Cervical
screening outside the private sector is very limited, covering at
most 5% of the poor women (unpublished data from Ministry of
Health, Family Planning Programme, 1997). Thus, as in most
developing countries, cervical cancer screening programmes in
Peru have had little or no impact in reducing the mortality of
cervical cancer. 
The recognition of a limited number of HPV types as the
primary cause of virtually all cervical cancers (Walboomers et al,
1999) has opened new perspectives for the prevention of this
malignancy. First, in primary prevention through the use of safe
and effective HPV vaccines currently being tested (Coursaget and
Muñoz, 1999), and second, in secondary prevention by intro-
ducing HPV testing into the screening programmes (Schiffman
et al, 2000). 
Both strategies require the identification of the relevant HPV
types causing cervical cancer in a given population. Towards this
aim, the IARC has been conducting a series of case-control studies
of cervical cancer in a number of developing countries. We report
here the results of an IARC study on invasive cervical cancer in
Peru to assess the risk associated with over 30 HPV types and the
role of co-factors. 
MATERIALS AND METHODS 
Study population 
Between April 1996 and July 1997, a total of 198 cases and 196
control women were recruited from two hospitals in Lima:
Instituto Nacional de Enfermedades Neoplasicas (INEN) and the
General Hospital Maria Auxiliadora. Cases were defined as
women residing in Lima Metropolitan area with a new histological
diagnosis of invasive cervical cancer at the INEN, who have not
received any previous treatment, and who were in reasonable
physical and mental condition to provide reliable responses to the
questionnaire. 
Controls were selected from women without cervical cancer or
prior history of treatment with conization or hysterectomy
attending the same hospital as the cases or the General Hospital.
They were selected using broad stratified age matching to the
cases within 10-year age groups. Exclusion criteria for the controls
included diseases associated with known risk factors for cervical
cancer such as cancers of the anogenital tract, tobacco-related
cancers and cancer of the breast, endometrium, ovary or colon.
The main diagnostic categories of the control subjects included:
cholecystitis (31%), inguinal or umbilical hernia (15%), appen-
dicitis (15%), skin diseases (11%), lymphomas and thyroid cancer
(11%), pyelonephritis and other infections (11%), benign tumours
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BJOC 01-1948 966-971  1/10/01  11:53 am  Page 966(6%), varices (3%), hydatid cysts (2%) and others (3%). The cyto-
logical diagnoses of the control women at recruitment were:
normal (62%), inflammatory (35%), low-grade squamous intraep-
ithelial lesion (3%). Written informed consent was obtained from
all women who participated in the study. The participation rate was
85% for cases and 80% for controls. 
Data and specimen collection 
All consenting women were administered a standardized question-
naire by female trained interviewers covering a demographic
characteristics, sexual behaviour, reproductive and contracep-
tive history, genital hygiene, tobacco smoking, coca chewing,
screening history and sexually transmitted diseases. 
A gynaecological examination was then performed with collec-
tion of biopsy specimens in the cases and exfoliated cells in the
controls. Necrosis and easy bleeding prevented taking adequate
scrapes from most cases. For controls, one Pap smear was
prepared and the remaining cells were eluted in phosphate-
buffered saline (PBS), pelleted in PBS and stored at –70˚ C for
later use for HPV DNA detection. Biopsy specimens from cases
were also stored at –70˚ C. 
The histological and cytological slides were reviewed by local
pathologists. 
The study protocol was cleared by the Ethical Committe of the
IARC and by a local ethical committee. 
HPV DNA detection and typing 
HPV DNA detection and typing was performed using PCR ampli-
fication methods at a central laboratory as previously described (de
Roda Husman et al, 1994; Jacobs et al, 1995). Briefly, DNA
quality was evaluated using β -globin primers and HPV DNA was
then amplified using the general primer set GP5+/6+. PCR prod-
ucts were assessed for HPV positivity by low-stringency Southern
blot hybridization using a cocktail of HPV specific probes
(Walboomers et al, 1992). For viral genotyping the HPV-positive
PCR products were successively hybridized with oligonucleotide
probes for 33 HPV types (6, 11, 16, 18, 26, 31, 33, 34, 35, 39, 40,
42, 43, 44, 45, 51, 52, 54, 56, 57, 58, 59, 61, 66, 68, 70, 72, 73,
IS39, MM4, MM7, CP6108 and CP8304). Viral DNA positive in
the GP5+/6+ PCR that did not hybridize with any of the provided
probes was arbitrarily named HPV X. 
In a second step, all 29 cases positive for β -globin DNA but
negative with the GP5+/6+ primers were reamplified with E7
primers for 14 high-risk HPV types (HPV 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66 and 68) (Walboomers et al, 1999). A
similar number of controls negative with GP5+/6+ primer PCR
were randomly selected from those within the same age group as
the cases and found positive for the E7 primer system. Of all the
GP5+/6+ negative cases (n = 29), 19 were positive with the E7
primer system, while 10 remained negative for HPV. No malignant
cells were observed in the tissue sections cut adjacent to those used
for HPV DNA detection in these 10 cases. On the other hand, none
of the retested controls (n = 18) were HPV DNA-positive with the
E7 primer system. 
Of the 394 specimens tested, 20 from controls (10.2%) and 
2 from cases (1%) were β -globin and HPV-negative (GP5+/6+
primers) and were excluded from statistical analyses. Also,
cervical cells from one control (0.5%) were missing, leaving 371
women with HPV data (196 cases and 175 controls). 
Statistical analysis 
Odds ratios (ORs) and 95% confidence intervals (Cls) were calcu-
lated as approximations of the relative risks by unconditional
logistic regression (Breslow & Day, 1980). ORs for the association
between histological types of cervical cancer and specific HPV
types were adjusted for age categorized in four age-groups (< 40,
40–49, 50–59, > 60). The ORs for the various HPV types were
calculated by comparing women who had the specific HPV types
(either as a single infection with this type or a multiple infection
containing this type) with women who were HPV DNA negative. 
To assess the role of risk factors other than HPV, a stratified
analysis restricted to HPV DNA positive cases and controls was
performed. Statistical significance was tested by the likelihood
ratio test for the difference for dichotomous variables and by two-
sided linear trend for variables in logically ordered categories. 
From variables that were highly correlated (using Pearson’s
correlation coefficients) and that may have been measuring the
same effect, one was selected for inclusion in the final model. 
RESULTS 
Out of the 198 cases of invasive cervical cancer, 173 (87.4%) were
diagnosed as squamous cell carcinoma, 15 (7.6%) as adenocarci-
noma and 10 (5%) as adenosquamous cell carcinomas. According
to the FIGO classification, 6 (3%) were categorized as stage I, 101
(51%) as stage II, 85 (43%) as stage III and 6 (3%) as stage IV. 
The overall HPV DNA prevalence was 94.9% in cases (95.3%
in squamous cell carcinomas and 92% in adenocarcinoma/
adenosquamous carcinomas) and 17.7% among control women
(Table 1). However, if we exclude the 10 HPV-negative cases in
which no malignant cells were observed in the tissue sections cut
adjacent to those used for HPV DNA detection, the prevalence of
HPV DNA in cases is 100%. 
Fifteen different HPV types were detected among women with
squamous cell carcinoma and among control women and five
among women with adenocarcinoma/adenosquamous carci-
nomas. The prevalence of multiple HPV infections among HPV-
positive women was 12.9% in squamous cell carcinomas, 8.7%
in adenocarcinoma and 22.6% in control women. Table 2 shows
that the most common type in women with squamous cell carci-
noma was HPV 16 followed by HPV types 18, 31, 52, 33 and 45.
In adenosquamous carcinomas HPV 16 was also the most
common type followed by HPV 35 and in adenocarcinoma, HPV
16 was the most common type (86%), followed by HPV 18
(21%). In control women, the most common types were HPV 16,
18, 56 and 31. 
In 8 (5%) of the women with squamous cell carcinoma and posi-
tive for HPV DNA and in 6 (19%) of the control women, the HPV
type could not be identified with the 33 type-specific probes that
we used and were classified as HPV X. All single HPV infection
were caused by high-risk or oncogenic HPV types, except for one
low-risk HPV type (11) involving a single control woman. Two
low-risk types identified in multiple infections (HPV 6, 42) were
found in combination with high-risk types and were also detected
in control women only. Among case women the HPV DNA preva-
lence did not vary with age. 
The age-adjusted ORs for the less common HPV types (HPV
33, 35, 39, 52) were as high as those for the most common HPV
types (HPV 16 and 18), for both squamous cell carcinomas and
adenocarcinomas/adenosquamous carcinomas. 
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To investigate the relevance of risk factors other than HPV, two
types of statistical analyses were performed: a multivariate
analysis adjusting for HPV and other potential confounders and a
stratified analysis in which only HPV DNA-positive women are
included. Only the results of the latter are considered and
presented (Table 3). This is because if HPV is the necessary cause
of cervical cancer, the role of cofactors should be envisioned only
in the progression from HPV carrier state to cancer, when dealing
with case-control studies. A significant increase in risk was
observed with ever pregnancy, in women who reported using oral
contraceptives (OCs) for 4 or more years (P = 0.005) and among
tobacco smokers and chewers of coca leaves. A significant reduc-
tion in risk (OR = 0.2; 95% CI = 0.06–0.6) was observed in those
reporting use of intra-uterine device as a contraceptive method. 
A non-significant increase in risk was observed with lack of
schooling, with being a widow, of starting sexual intercourse
before 15 years of age and ever practising anal intercourse. Having
had more than three lifetime Pap smears and the fact of using sani-
tary towels were associated with a non-significant reduction in
risk. No significant association was detected with the number of
sexual partners. 
Among control women, the HPV DNA prevalence was lower in
women under 40 years of age (10.5%) than among women over
40 (20%), but the difference was not statistically significant
(P = 0.20). The small number of HPV DNA-positive controls
precluded the identification of risk factors for HPV DNA-
positivity. 
DISCUSSION 
This, the first case-control study of the subject in Peru, revealed
that HPV infection is the primary cause of both squamous cell
carcinomas and adenocarcinomas/adenosquamous carcinomas in
Peru. This is consistent with similar studies carried out by the
IARC in Spain and Colombia (Muñoz et al, 1992; Bosch et al,
1993), the Philippines (Ngelangel et al, 1998), Thailand
(Chichareon et al, 1998), Brazil (Eluf-Neto et al, 1994), Morocco
(Chaouki et al, 1998) and Paraguay (Rolón et al, 2000). 
Table 1 Type-specific HPV prevalence in cervical cancer patients and control women 
HPV type Squamous cell carcinoma Adenocarcinoma/adenosquamous  Controls
carcinoma
n%n %n %
Negative 8 4.7 2 8.0 144 82.3 
Positive for any type 163 95.3 23 92.0 31 17.7 
Total 171 100.0 25 100.0 175 100.0 
HPV 11 0 0.0 0 0.0 1 3.2 
HPV 16 89 54.9 18 78.3 5 16.1 
HPV 18 10 6.2 1 4.4 1 3.2 
HPV 31 14 8.6 0 0.0 1 3.2 
HPV 35 1 0.6 1 4.4 1 3.2 
HPV 45 2 1.2 0 0.0 0 0.0 
HPV 51 1 0.6 1 4.4 2 6.5 
HPV 52 10 6.2 0 0.0 1 3.2 
HPV 56 1 0.6 0 0.0 4 12.9 
HPV 58 2 1.2 0 0.0 1 3.2 
HPV 59 1 0.62 0 0.0 0 0.0 
HPV 66 2 1.2 0 0.0 0 0.0 
HPV 70 0 0.0 0 0.0 1 3.23 
HPV X 8 4.9 0 0.0 6 19.4 
HPV 6 + 31 0 0.0 0 0.0 1 3.2 
HPV 16 + 18 0 0.0 1 4.4 1 3.2 
HPV 16 + 31 1 0.6 0 0.0 0 0.0 
HPV 16 + 42 0 0.0 0 0.0 1 3.2 
HPV 16 + 52 1 0.6 0 0.0 0 0.0 
HPV 18 + 31 1 0.6 0 0.0 0 0.0 
HPV 18 + 33 2 1.2 0 0.0 0 0.0 
HPV 18 + 45 3 1.9 1 4.4 0 0.0 
HPV 18 + 52 0 0.0 0 0.0 1 3.2 
HPV 18 + 58 1 0.6 0 0.0 0 0.0 
HPV 31 + 39 1 0.6 0 0.0 0 0.0 
HPV 31 + 52 2 1.2 0 0.0 0 0.0 
HPV 31 + 68 0 0.0 0 0.0 1 3.2 
HPV 33 + 35 2 1.2 0 0.0 0 0.0 
HPV 39 + 45 1 0.6 0 0.0 0 0.0 
HPV 52 + 56 1 0.6 0 0.0 0 0.0 
HPV 70 +CP8304 1 0.6 0 0.0 1 3.2 
HPV 18 + 33 + 35 1 0.6 0 0.0 0 0.0 
HPV 18 + 39 + 45 1 0.6 0 0.0 0 0.0 
HPV 18 + 33 + 35 + 39 1 0.6 0 0.0 0 0.0 
HPV 18 + 33 + 35 + 45 1 0.6 0 0.0 0 0.0 
HPV 18 + 33 + 39 + 58 1 0.6 0 0.0 1 3.2 
Total multiple types 22 13.5 2 8.7 7 22.6 
Percentage of the single and multiple types were calculated based on the total HPV positive women.
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HPV DNA ascertainment in cases was done using first L1
primers (GP5+/6+ primers) and subsequently E7 primers in
those found HPV-negative with the L1 primers. This retesting
increased the HPV DNA prevalence from 85.2% to 94.9%. To
assess the possibility that the same could have happened among
control women, 18 specimens from control women originally
classified as HPV DNA-negative using GP5+/6+ primers and of
similar age distribution as the 19 cases retested and found HPV
DNA-positive with the E7 primers, were also retested with E7
primers. None of these women were found HPV DNA-positive.
This suggests that an underestimation of HPV DNA prevalence
in controls leading to an overestimation of the ORs for invasive
cervical cancer, is unlikely. The six most common HPV types
among cases were: HPV 16 (59.1%), HPV 18 (13.4%), HPV 31
(10.2%), HPV 52 (7.5%), HPV 45 (4.8%) and HPV 33 (4.3%).
This type distribution in Peru is similar to that observed in other
Latin-American countries (Brazil, Colombia and Paraguay)
where HPV types 16, 18 and 31 were the three most common.
However, in Peru the fourth and fifth most common types were
HPV 52 and 45, while in the other three countries they were
HPV 45 and 33. In Latin America, the relative high prevalence
of HPV 52 in cervical cancer would appear to be confined to
Peru. Among control women, the most common types found
(HPV 16, 18) were the same as in women with invasive cervical
cancer. 
Our results allowed the estimation of the risk of cervical cancer
linked to the 9 HPV types most common in this population (HPV
16, 18, 31, 52, 33, 45, 35, 39 and 58). Women in whom two or
more different HPV types were detected, did not have a higher risk
of cervical cancer than those in whom a single HPV type was
detected. 
In only 10 cases (5%) HPV DNA could not be detected. It is of
interest to note that no malignant cells were observed in the snap-
frozen sections of the biopsies that were cut adjacent to those
sections used for HPV DNA detection in these 10 cases. Only
stroma or necrotic tissue was found in these HPV DNA-negative
tissue sections. Thus, if these 10 cases are excluded, the preva-
lence of HPV DNA in cases would be 100%. These findings are
consistent with the results of our IARC international survey based
on 1000 cervical cancer biopsy specimens from 22 countries. An
initial HPV DNA prevalence of 93% was obtained when L1
primers were used in the initial HPV testing. However, when the
specimens originally classified as HPV DNA-negative were
retested with E7 primers and strict control of the presence of
Table 2 Odds ratios (ORs) for the association between histological types of cervical cancer and HPV types 
Case subjects 
Squamous cell carcinoma Adenocarcinoma/adenosquamous carcinoma Controls 
HPV type (1) n % OR* (95% Cl) n % OR* (95% Cl) n % 
Negative 8 4.7 1.0 2 8.0 1.0 144 82.3 
(referent) (referent) 
Positive for any type 163 95.3 102.0 23 92.0 51.4 31 17.7 
(44.5–236) (11.4–232) 
Total 171 100.0 115.9 25 100.0 175 100.0 
(48.8–276) 
HPV 16 91 55.8 255.0 19 82.6 241 7 22.6 
(85.6–759) (40.8–1425) 
HPV 18 22 13.5 149.0 3 13.0 40.5 4 12.9 
(33.5–622) (4.5–364) 
HPV 31 19 11.7 238.3 0 0.0 – 3 9.7 
(39.8–1427) 
HPV 33 8 5.0 342.8 0 0.0 – 1 3.2 
(26.7–4400) 
HPV 35 6 3.7 227.8 1 4.4 72.0 1 3.2 
(17.7–2926) (3.2–1604)
HPV 39 5 3.1 176.5 0 0.0 – 1 3.2 
(12.7–2448) 
HPV 45 8 4.9 ∞ 1 4.4 ∞ 0 0.0 
(33.5–∞ ) 
HPV 52 14 8.6 190.3 0 0.0 – 2 6.5 
(28.1–1289) 
HPV 58 4 2.5 66.5 0 0.0 – 2 6.5 
(8.0–554) 
HPV X 8 4.9 37.8 0 0.0 – 6 19.4 
(8.2–174.3) 
Other types (2) 7 4.3 12.6 1 4.4 – 12 38.7 
(3.5–45.4) 
Single infection 141 86.5 161.9 21 91.3 66.6 24 77.4 
(59.4–441) (14.1–314) 
Multiple infection 21 12.9 66.6 2 8.7 19.1 7 22.6 
(14.1–314) (2.1–175) 
Percentage of the single and multiple types were calculated based on the total HPV positive women. *Age-adjusted (1) HPV from both single and multiple
infection included.(2) includes HPV types 6, 11, 42, 51, 56, 59, 66, 68, 70, CP8304.
BJOC 01-1948 966-971  1/10/01  11:53 am  Page 969970 C Santos et al  
British Journal of Cancer (2001) 85(7), 966–971 © 2001 Cancer Research Campaign
malignant cells was done, the prevalence increased to 99.7%
(Walboomers et al, 1999). 
Our results indicate that HPV is the primary and probably a
necessary cause of cervical cancer in Peru. However, it is not a
sufficient cause. To assess the role of cofactors in this and in our
previous studies, we have used two analytical strategies. In the
first, we included all women independently of their HPV DNA
status, and accounted by the strong effect of HPV by statistical
adjustment. However, this type of adjustment is inappropriate if
we consider that a small proportion of cases are most probably
false negative, and the vast majority of controls are not carriers of
HPV and therefore not at risk of developing cervical cancer. Thus,
we have presented here only the results obtained with the second
strategy, that is, restricting the analysis to HPV DNA-positive
cases and controls. However, because of the small number of HPV
DNA-positive controls, our ability to detect significant associa-
tions is rather limited. Despite the above, our analyses restricted to
HPV DNA-positive women allowed the identification of long-
term use (> 5 years) of OCs as the principal cofactor in this popu-
lation. 
Long-term use of OCs was also identified as a cofactor in our
studies in Spain and Colombia (Bosch et al, 1994); Brazil (Eluf-
Neto et al, 1994), the Philippines (Ngelangel et al, 1998), Morocco
(Chaouki et al, 1998) and Paraguay (Rolon et al, 2000). However,
the association of OC use and CIN-3 appears to be less consistent;
while some studies have reported an increased risk with long-term
use (Muñoz et al, 1993; Lacey et al, 1999), others have not found a
clear association (Deacon et al, 2000). The mechanism by which
OCs increase the risk of cervical cancer in carriers of HPV DNA
has not been elucidated. It has been suggested that steroid
hormones may facilitate the integration of HPV DNA (Mittal et al,
1993). 
There was also a suggestion that pregnancy, smoking and
chewing coca leaves may be potential cofactors. The epidemiolog-
ical evidence linking smoking with cervical cancer is controversial
(Szarewski and Cuzick, 1998). Analyses of HPV DNA-positive
cases and controls have shown an association with smoking in
some of our previous studies (Chichareon et al, 1998; Ngelangel
et al, 1998), but not in others (Bosch et al, 1992; Eluf-Neto et al,
1994). A clear increased risk and a significant dose-response rela-
tionship for CIN-3 have been recently reported (Deacon et al,
2000). The association with the habit of chewing coca leaves is
intriguing, but it is based on small numbers. 
In summary, our study has identified the HPV types causing
cervical cancer in Peru and also long-term use of oral OCs,
smoking and coca chewing as potential cofactors. Lack of power
due to the small number of HPV DNA-positive controls in each
study precluded definitive conclusions. A proper evaluation of
these cofactors is currently underway in a pooled analysis of all
our case-control studies. 
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Table 3 Cofactors for cervical cancer among HPV DNA-positive women 
Variable % Cases % Controls OR1 (95% Cl) OR2 (95% Cl) 
(n = 186) (n = 31) 
Pregnancy 
Never 1.6 9.7 1.0 1.0 
Ever 98.4 90.3 5.8 (1.1–30.8) 3.5 (0.6–19.7) 
No. of full-term pregnancies 
0 1.6 9.7 1.0 1.0 
1–2 15.0 9.7 7.8 (1.0–59.2) 5.9 (0.8–45.8) 
3–5 39.3 41.9 4.6 (0.8–26.3) 2.7 (0.5–16.1) 
≥ 6 44.1 38.7 6.5 (1.1–36.9) 3.6 (0.6–22.0) 
P = 0.02 P = 0.76 
Oral contraceptive use 
Never 67.2 83.9 1.0 1.0 
Ever 32.8 16.1 2.6 (0.9–7.6) 2.7 (0.9–8.4) 
Never 67.2 83.0 1.0 
≤ 3 12.9 16.1 1.0 (0.3–2.9) 
≥ 4 18.8 0.0 ∞ (1.9–∞ ) 
Unknown 1.1 0.0 
P = 0.005 
IUD use 
Never 88.2 71.0 1.0 1.0 
Ever 11.8 29.0 0.3 (0.1–0.7) 0.2 (0.06–0.6) 
Smoking 
Never 90.3 100.0 1.0 
Ever 9.7 0.0 ∞ (0.8–∞ ) 
P = 0.08 
Coca chewing 
Never 93.0 100.0 1.0 
Ever 7.0 0.0 ∞ (0.6–∞ ) 
P = 0.22 
OR1 = Odds ratios adjusted for age; OR2 = Odds ratios adjusted for age, screening history, age at first intercourse, ever pregnancy, ever
use of oral contraceptives. 
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